Research Topics
| Catherine OrrellSummaryAffiliation: University of Cape Town Country: South Africa Publications
| Collaborators
|
Detail Information
Publications
Adherence is not a barrier to successful antiretroviral therapy in South AfricaCatherine Orrell
Diana, Princess of Wales HIV Research Unit, Somerset Hospital, University of Cape Town, South Africa
AIDS 17:1369-75. 2003..Speaking the same language as site staff and simplified dosing frequency were beneficial. Socio-economic status had no impact on adherence and should not be used as a limitation to ART access...- Conservation of first-line antiretroviral treatment regimen where therapeutic options are limitedCatherine Orrell
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
Antivir Ther 12:83-8. 2007.... 
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeCatherine Orrell
Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Antivir Ther 14:523-31. 2009..This study aimed to evaluate HIV type-1 (HIV-1) drug resistance pretreatment and in those failing first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in South Africa...- Antiretroviral adherence in a resource-poor settingCatherine Orrell
Desmond Tutu HIV Centre, IIDMM, Werner Beit Building North, Medical School, Anzio Road, Observatory, Cape Town 7925, South Africa
Curr HIV/AIDS Rep 2:171-6. 2005..Major factors contributing to adherence or nonadherence are whether the drug is accessed for free or is self-funded, patient preparedness for use of ART, stigmatization related to being HIV-positive, and ease of use of regimen... - Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?Catherine Orrell
Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Antivir Ther 16:527-34. 2011..Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations... - Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluationStephen D Lawn
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Clin Infect Dis 43:770-6. 2006..Understanding the determinants of key outcome measures--including death and nondeath losses--would assist in program evaluation and development... - When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness studyMotasim Badri
Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine, University of Cape Town, South Africa
Antivir Ther 11:63-72. 2006..However, cost-effectiveness of initiating treatment at different CD4 count thresholds has not been explored in resource-poor settings... 
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South AfricaMweete D Nglazi
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
J Acquir Immune Defic Syndr 56:e1-8. 2011..To assess sustainability of programmatic outcomes in a community-based antiretroviral therapy (ART) service in South Africa during 7 years of scale-up...- Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South AfricaLinda Gail Bekker
Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town
S Afr Med J 96:315-20. 2006..Despite rapid expansion of antiretroviral therapy (ART) in sub-Saharan Africa there are few longitudinal data describing programme performance during rapid scale-up... - Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trialIan Sanne
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Lancet 376:33-40. 2010..We compared outcomes of nurse versus doctor management of ART care for HIV-infected patients... - Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South AfricaStephen D Lawn
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, South Africa
AIDS 23:335-42. 2009..To determine the relationship between mortality risk and the CD4 cell response to antiretroviral therapy (ART)... - Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factorsKatharina Kranzer
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, South Africa
J Acquir Immune Defic Syndr 55:e17-23. 2010..To investigate antiretroviral treatment (ART) interruption in a long-term treatment cohort in South Africa... - Linkage to HIV care and antiretroviral therapy in Cape Town, South AfricaKatharina Kranzer
Department of Medicine, Faculty of Health Sciences, The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
PLoS ONE 5:e13801. 2010..Programme reports typically focus on loss to follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of individuals prior to starting ART... - Healthcare utilization of patients accessing an African national treatment programGuy Harling
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
BMC Health Serv Res 7:80. 2007..Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced... - Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South AfricaLisa Noelle Ncaca
Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa
PLoS ONE 6:e23088. 2011..Understanding of the impact of non-structured treatment interruption (TI) and variation in tablet-taking on failure of first-line antiretroviral therapy (ART) is limited in a resource-poor setting... - Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme designStephen D Lawn
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Cape Town, South Africa
AIDS 19:2141-8. 2005..To determine rates, risk factors and causes of death among patients accessing a community-based antiretroviral treatment (ART) programme both prior to and following initiation of treatment... - Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatmentRichard Kaplan
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
AIDS 22:1679-81. 2008..This finding highlights the need for programmatic interventions to address retention in care for this patient population... - Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppressionMweete D Nglazi
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, and the Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
PLoS ONE 8:e57907. 2013..To determine the proportion, characteristics and outcomes of patients who transfer-out from an antiretroviral therapy (ART) service in a South African township... - Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelinesMotasim Badri
Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine, University of Cape Town, Observatory, South Africa
AIDS 18:1159-68. 2004.... - Effect of caregivers' depression and alcohol use on child antiretroviral adherence in South AfricaHeather B Jaspan
Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
AIDS Patient Care STDS 25:595-600. 2011..99). Pediatric adherence is affected by caregiver alcohol use, but caregiver relationship to the child is most important. This small study suggests that interventions should aim to keep mothers healthy and alive, as well as alcohol-free... - Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapyCatherine Orrell
Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town 7925, South Africa
AIDS Res Treat 2011:469127. 2011..While 67% of those who experience initial virological breakthrough resuppress after an adherence intervention, these individuals are significantly less likely be retained in care than those who remain virologically suppressed throughout... - Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tabletsEric H Decloedt
Division of Clinical Pharmacology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
Antimicrob Agents Chemother 55:3195-200. 2011..Doubling the dose of the tablet formulation of LPV/r overcomes induction by rifampin. Less hepatotoxicity occurred in our cohort of HIV-infected participants than was reported in healthy-volunteer studies... - Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settingsStephen D Lawn
Lancet Infect Dis 6:385-6; author reply 387-8. 2006 - Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedOlivia Keiser
Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
PLoS Med 5:e148. 2008..We compared virologic response, changes to first-line regimens, and mortality in HIV-infected patients starting HAART in South Africa and Switzerland... - Antiretroviral therapy in a community clinic--early lessons from a pilot projectLinda-Gail Bekker
HIV Research Unit, University of Cape Town, Provincial Administration of the Western Cape
S Afr Med J 93:458-62. 2003..Attention must be given to the diagnosis of tuberculosis during screening and early ART. Incorporating therapeutic counsellors into the programme increased community involvement and utilised a valuable and previously untapped resource... - Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programmeStephen D Lawn
AIDS 19:2050-2. 2005